ArticleRespiratory research2026
USP4 promotes non-small cell lung cancer tumorigenesis by antagonizing CNOT4-mediated degradation of PAF1.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) is a leading cause of cancer mortality. This study examines whether the deubiquitinase USP4 promotes NSCLC progression by stabilizing PAF1 and opposing the E3 ligase CNOT4.
methodsUSP4 and PAF1 expression were examined in NSCLC cell lines and paired tumor tissues by Western blotting and RT-qPCR. Functional studies included USP4 overexpression or silencing, proteasome inhibition, and rescue assays with PAF1. Co-immunoprecipitation and ubiquitination analyses were performed to confirm protein interaction and K48-linked ubiquitin modification. Cellular proliferation was assessed using CCK-8 assays, and the oncogenic role of USP4 in vivo was evaluated through A549 xenograft models co-expressing USP4 and/or CNOT4, followed by histological and Ki-67 analyses.
resultsUSP4 and PAF1 were concomitantly upregulated in NSCLC cells and tissues, displaying a strong positive correlation. In addition, in-silico analysis of available NSCLC datasets showed that high USP4 or PAF1 expression was associated with poorer overall survival, whereas high CNOT4 expression was associated with better overall survival. USP4 enhanced PAF1 protein stability by directly binding and reducing its K48-linked polyubiquitination, independent of transcriptional regulation. Functionally, USP4 promoted NSCLC cell proliferation and rescued CNOT4-induced PAF1 degradation. In vivo, USP4 expression restored tumor growth and proliferation suppressed by CNOT4, confirming its antagonistic role in tumorigenesis.
conclusionUSP4 stabilizes PAF1 by counteracting CNOT4-mediated ubiquitination and degradation, thereby promoting NSCLC progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.